Alumis (ALMS) news
Recent news
Alumis - Over 80% of Onward3 patients maintain clear or almost clear scalp skin at 48 weeks
Alumis Inc. (NASDAQ: ALMS) recently reported long-term data from its Onward3 clinical trial, indicating that more than 80% of patients treated with its investigational therapy maintained clear or almost clear scalp skin at 48 weeks [1]. The findings, derived from an ongoing study, highlight the…
AInvest Wire · 6d agoAlumis - Plans NDA submission for envudeucitinib in 4Q 2026
AInvest Wire · 6d agoAlumis announces new phase 3 data demonstrating envudeucitinib rapidly and durably improved psoriasis burden across scalp, itch, and quality of life measures
AInvest Wire · 6d agoAlumis Inc.: Oppenheimer cuts target price to $37 from $55
AInvest Wire · Sep 2, 2026Alumis Inc.: H.C. Wainwright cuts to buy from neutral
H.C. Wainwright has revised its rating for Alumis Inc. (NASDAQ: ALMS), upgrading from "neutral" to "buy," according to recent reports. Previously, the firm had maintained a "neutral" rating with a $25 price target, which aligned closely with the stock's market price of $24.99 at the time. The…
AInvest Wire · Sep 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.